Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

The Lancet - Tập 377 Số 9769 - Trang 905-913 - 2011
Peter Malfertheiner1, Franco Bazzoli2, Jean‐Charles Delchier3, Krzysztof Celiński4, Monique Giguère5, Marc Rivière5, Françis Mégraud6
1Gastroenterologie, Hepatologie und Infektiologie, Otto-von-Guericke-Universtität, Magdeburg, Germany
2Department of Clinical Medicine, University of Bologna, Bologna, Italy
3AP-HP, Groupe Hospitalier Henri Mondor, Service d'Hépatogastroentérologie et Centre d'Investigation Clinique 006, Créteil, France
4Department of Gastroenterology, Medical University of Lublin, Lublin, Poland
5Axcan Pharma Inc, Mont-Saint-Hilaire, QC, Canada
6INSERM U853, Université Victor Segalen Bordeaux 2, Bordeaux, France

Tóm tắt

Từ khóa


Tài liệu tham khảo

Moayyedi, 2004, Helicobacter pylori public health implications, Helicobacter, 9, 67, 10.1111/j.1083-4389.2004.00250.x

Suerbaum, 2002, Helicobacter pylori infection, N Engl J Med, 347, 1175, 10.1056/NEJMra020542

Malfertheiner, 2009, Peptic ulcer disease, Lancet, 374, 1449, 10.1016/S0140-6736(09)60938-7

Malfertheiner, 2007, Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report, Gut, 56, 772, 10.1136/gut.2006.101634

Asaka, 2010, Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition, Helicobacter, 15, 1, 10.1111/j.1523-5378.2009.00738.x

Chey, 2007, American College of Gastroenterology guideline on the management of Helicobacter pylori infection, Am J Gastroenterol, 102, 1808, 10.1111/j.1572-0241.2007.01393.x

Fock, 2009, Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection, J Gastroenterol Hepatol, 24, 1587, 10.1111/j.1440-1746.2009.05982.x

Fukase, 2008, Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial, Lancet, 372, 392, 10.1016/S0140-6736(08)61159-9

Graham, 2005, Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori, Aliment Pharmacol Ther, 21, 165, 10.1111/j.1365-2036.2005.02322.x

O'Morain, 2003, Efficacy and safety of single triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole for eradication of Helicobacter pylori: an international multicenter study, Aliment Pharmacol Ther, 17, 415, 10.1046/j.1365-2036.2003.01434.x

Laine, 2003, Am J Gastroenterol, 98, 562, 10.1111/j.1572-0241.2003.t01-1-07288.x

De Francesco, 2010, Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits, J Antimicrob Chemother, 65, 327, 10.1093/jac/dkp445

Graham, 2010, Helicobacter pylori treatment in the era of increasing antibiotic resistance, Gut, 59, 1143, 10.1136/gut.2009.192757

Mégraud, 2004, H pylori antibiotic resistance: prevalence, importance, and advances in testing, Gut, 53, 1374, 10.1136/gut.2003.022111

Hillemand, 1977, Bismuth treatment and blood bismuth levels, Sem Hop, 53, 1663

De Francesco, 2007, Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy, J Antimicrob Chemother, 59, 783, 10.1093/jac/dkm005

Blaser, 2002, The genetic gymnastics of our indigenous microbes, N Engl J Med, 346, 2083, 10.1056/NEJMcibr020229

Koletzko, 2006, Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe, Gut, 55, 1711, 10.1136/gut.2006.091272

Boyanova, 2009, Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria, J Med Microbiol, 58, 930, 10.1099/jmm.0.009993-0

Mégraud, 2007, Helicobacter pylori detection and antimicrobial susceptibility testing, Clin Microbiol Rev, 20, 280, 10.1128/CMR.00033-06

Graham, 2000, Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study, Aliment Pharmacol Ther, 14, 745, 10.1046/j.1365-2036.2000.00770.x

Goodwin, 1988, Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies, J Clin Pathol, 41, 207, 10.1136/jcp.41.2.207

Tsugawa, 2011, Two amino acids mutation of ferric uptake regulator determines Helicobacter pylori resistance to metronidazole, Antioxid Redox Signal, 14, 15, 10.1089/ars.2010.3146

Ford, 2008, Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis, World J Gastroenterol, 14, 7361, 10.3748/wjg.14.7361

Chiba, 2000, Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens, Can J Gastroenterol, 14, 885, 10.1155/2000/709640

Luther, 2010, Empiric quadruple vs triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability, Am J Gastroenterol, 105, 65, 10.1038/ajg.2009.508

Bader, 1987, The safety profile of De-Nol, Digestion, 37, 53, 10.1159/000199559

Buge, 1974, 20 cases of acute encephalopathy with myoclonia during treatment with oral bismuth salts, Ann Med Intern, 124, 877

Slikkerveer, 1989, Pharmacokinetics and toxicity of bismuth compounds, Med Toxicol Adverse Drug Exp, 4, 303, 10.1007/BF03259915

Mégraud, 2005, Update on therapeutic options for Helicobacter pylori-related diseases, Curr Infect Dis Rep, 7, 115, 10.1007/s11908-005-0071-4

Fuccio, 2007, Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication, Ann Intern Med, 147, 553, 10.7326/0003-4819-147-8-200710160-00008

Saad, 2006, Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis, Am J Gastroenterol, 101, 488, 10.1111/j.1572-0241.2006.00637.x

Jadad, 1996, Assessing the quality of reports of randomized clinical trials: is blinding necessary?, Control Clin Trials, 17, 1, 10.1016/0197-2456(95)00134-4

Zagari, 2007, Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER study, Gut, 56, 475, 10.1136/gut.2006.102269

Glupczynski, 2002, Comparison of the E test and agar dilution method for antimicrobial susceptibility testing of Helicobacter pylori, Eur J Clin Microbiol Infect Dis, 21, 549, 10.1007/s10096-002-0757-6

Fischbach, 2007, Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori, Aliment Pharmacol Ther, 26, 343, 10.1111/j.1365-2036.2007.03386.x

Essa, 2009, Meta-analysis: four-drug, three antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication, Helicobacter, 14, 109, 10.1111/j.1523-5378.2009.00671.x

Graham, 2008, New concepts of resistance in the treatment of Helicobacter pylori infections, Nat Clin Pract Gastroenterol Hepatol, 5, 321, 10.1038/ncpgasthep1138

Gisbert, 2010, Sequential therapy for Helicobacter pylori eradication: a critical review, J Clin Gastroenterol, 44, 313, 10.1097/MCG.0b013e3181c8a1a3